4 years ago

Apollo Therapeutics Secures $145 Million to Advance Treatments

  • Apollo Therapeutics, a Cambridge UK-based biopharmaceutical company, has raised $145 million in funding led by Patient Square Capital

  • The company plans to use the funds to advance its pipeline into development across oncology, major inflammatory disorders and rare disease, expand its U.S

  • operations in Boston area, and pursue collaborations globally with leading academic institutions.

      • ProblemHealthcare

      "Many diseases, such as cancers, inflammatory disorders, and rare diseases, lack effective treatments. Current treatments often have limited efficacy, severe side effects, and high costs."

      Solution

      "Apollo Therapeutics is developing transformative treatments based on breakthrough discoveries. They evaluate potential treatments based on their biological hypothesis, differentiated mechanisms, and technology compared to existing treatments. The company's focus is on creating treatments that are more effective, have fewer side effects, and are more affordable."

      Covered on